Celaid Therapeutics Completes Second Close of Series B Financing Round

CLD-001Positive

AI Analysis

Summary

Celaid Therapeutics completed the second close of its Series B financing round with Shionogi and Teikoku Ventures joining as new investors to accelerate U.S. clinical trial preparations for CLD-001.

Outcome Details

Second close of Series B financing round completed

Importance:5/10

Sentiment:

0.60

Series B FinancingCapital RaiseU.S. Clinical TrialsCLD-001

Related Companies

$SGIOY

Read the original article

Published by PR Newswire Biotech on October 5, 2026 1:30 AM

Read Original